Cite
Weisberg EL, Puissant A, Stone R, et al. Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase. Oncotarget. 2017;8(32):52026-52044doi: 10.18632/oncotarget.19036.
Weisberg, E. L., Puissant, A., Stone, R., Sattler, M., Buhrlage, S. J., Yang, J., Manley, P. W., Meng, C., Buonopane, M., Daley, J. F., Lazo, S., Wright, R., Weinstock, D. M., Christie, A. L., Stegmaier, K., & Griffin, J. D. (2017). Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase. Oncotarget, 8(32), 52026-52044. https://doi.org/10.18632/oncotarget.19036
Weisberg, Ellen L, et al. "Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase." Oncotarget vol. 8,32 (2017): 52026-52044. doi: https://doi.org/10.18632/oncotarget.19036
Weisberg EL, Puissant A, Stone R, Sattler M, Buhrlage SJ, Yang J, Manley PW, Meng C, Buonopane M, Daley JF, Lazo S, Wright R, Weinstock DM, Christie AL, Stegmaier K, Griffin JD. Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase. Oncotarget. 2017 Jul 06;8(32):52026-52044. doi: 10.18632/oncotarget.19036. eCollection 2017 Aug 08. PMID: 28881711; PMCID: PMC5581010.
Copy
Download .nbib